Member Info for 5085

With all the court cases looming, platinum now 10% lower than when they didn’t sell their concentrate and the buyer playing hide and seek it does appear Eurasia need a change in fortune.

In 2022 the Group took a decision to postpone the sale of platinum and other metals due to a strong Ruble and low platinum price. Stock available at 31 December 2022 represents platinum concentrate ready for refining, which was valued (i) using methodology set in the refining and sale and purchase agreement made with local refinery in 2021 and (ii) exchange rate and metal prices at 31 December 2022. The Group recognised an impairment loss on (i) the investment made to build a joint venture with Rosgeo (Note 15) due to uncertainty of any near-term development in that regard due to limitations enforced by current sanctions legislation (ii) a loss on an investment in to a UK “waste to electricity” project the Company decided not to immediately carry through to binding agreements

Https://industrytoday.co.uk/pharmaceutical/blood-screening-market-size-share-growth-trends-industry-report-2030#

Eurasia are mining experts who own mining leases in Russia, they are looking to sell off some or all of their assets. Is it normal for such a small loss making enterprise to be involved in so many legal issues?

DR you seem well informed, more so than your average shareholder, are you a company employee. I only ask that because you state your points, of which there are many, in a factual manner not as an opinion.

Toffers the SP is the only unbiased metric that shows who is winning - currently right/wrong. The bulls have very little in the way of substance to fight their corner. Name calling and such like is just playground stuff. If investors are unhappy they should target their displease at the BOD not someone on a chat board that said the SP was going to go down, when it went down ha-ha.

Toffers, how many things mentioned in an RNS did become reality?

If you ran a mining company is Russia and you had a stockpile of concentrate, would you place it in a padlocked shed and just ignore it or would you sell it as soon as possible?

It’s like the 2 fund raises £28m + £15m massive sums of money, £20m loaned out to god knows who and the rest?

Everywhere you look with this company there’s someone unusual.

Strange how they went from £30m in the bank to struggling to settle a tiny invoice #stinks

The part I found interesting on the video was the 90%+ gross margin on CiRT especially when you consider they have just secured a BUPA UK contract and they have an annual revenue figure close to £2bn

This goes more into detail on CiRT

https://www.youtube.com/watch?v=ZFbBpMUWmTo&t=1739s

Helium is now a lot more expensive

The Northern Territory (EPA 155) Hydrocarbon & Helium Project, (Mt Winter Project), will facilitate the drill testing of a large & potentially shallow seismically defined Neoproterozoic subsalt basal petroleum & Helium prospect in the Amadeus Basin centred upon the conditional re-entry and deepening of Mt Winter #1, a well drilled in 1981 and reaching TD in 1982. The prospect, within the Mt Winter Project area, has an apparent aerial closure of an estimated 13 km2 plus, (3,200 acres) with potential to host a TCFG scale resource of gaseous hydrocarbons with high concentrations of Helium, similar to the gas flows tested at Mt Kitty 1 and Magee 1 in the Amadeus Basin of the Northern Territory & probably present in the enormous STO/CTP JV Dukas prospect to the south which remains untested to date.

Overlying salt formations are regarded as being essential to trap Helium in any reasonable concentration during the long geological periods necessary for Helium to be generated by the decay of radiogenic minerals in basement granitoids. Estimates of potentially recoverable hydrocarbons and Helium from the prognosed basal subsalt Heavitree Quartzite in the gaseous state based on reasonable fundamentals with comparative justification at P50 Prospective Recoverable (SPE PMRS) unrisked level are c.1.5 TCFGE (Trillion Cubic Feet Equivalent) hydrocarbons and c.75 BCFG (75 million MCF) Helium respectively.

Grade-A (or 99.99% purity) industrial helium was priced at $280/MCF in the BLM August 2018 auction, (“Helium –Macro View Update” February 2019 Published by Edison Investment Research) so a gross “in the ground” value of this quantity of Helium (without reference to extraction costs or NPV calculations) may be in the order of US$20 billion, subject of course to verification of the volumetrics by the proposed exploration and test drilling programme.

EP 145 is part of the Gillen formation.

Why this is considered a world class helium play?

The first well to test the Heavitree–Gillen play was Magee 1, drilled by Pacific Oil and Gas in 1992 (Figure 1). The well was located near the interpreted depositional edge of the Heavitree Formation, and flowed low-rate gas containing hydrocarbons and helium from a thin Heavitree Formation reservoir. More than 20 years lapsed before a second test of the Heavitree–Gillen play was conducted in 2013–14 when Santos drilled Mt Kitty 1, some 140 km south-west of Magee 1. Mt Kitty 1 did not intersect the Heavitree Formation but flowed gas containing hydrocarbons and helium from fractured granitic basement. This test confirmed the existence of an extensive sub-salt petroleum system, as well as the excellent sealing capacity of the Neoproterozoic evaporites.

A much thicker Gillen Formation evaporite succession than originally prognosed was encountered. In total, Dukas 1ST1 intersected ~2300 m of Gillen Formation evaporites, comprising primarily anhydrite and halite. The top of the Gillen Formation evaporites, comprising massive anhydrite, was intersected at 1375 m MDRT, with the first halite encountered at 2104 m MDRT. Significant overpressure below a deeper, thick halite interval, and encouraging gas shows including helium, confirmed the excellent sealing capacity of the Gillen

Https://www.cnbctv18.com/healthcare/doctors-are-worried-as-the-world-is-running-out-of-helium-here-is-why-15052831.htm

You can see why the excitement with this just off to the east

https://www.energy-pedia.com/news/australia/central-petroleum-provides-resource-estimates-for-three-sub-salt-exploration-wells-targeting-helium--hydrogen-and-natural-gas-191216

Https://www.theaustralian.com.au/business/stockhead/greenvales-new-advanced-helium-natural-hydrogen-play-a-springboard-for-growth/news-story/b4ca07cc8132c373a41613662ddc3b9a

As we move closer to the drill turning, excitement here will be at fever pitch. The savvy book an early seat.

Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877825/#:~:text=Genomic%20profiling%20of%20tumors%20can,with%20breast%20or%20lung%20cancer.&text=Precision%20medicine%2C%20integrated%20into%20healthcare,that%20maximize%20safety%20and%20efficiency.

When the share price is north of £100, long-term investors can take comfort in the fact they came here at the ground level and helped this innovative company grow into a massive organisation off the back of reducing stress and suffering within the general public.

Currently testing Episwitch, early signs are positive

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of the Mitsubishi Chemical Group, is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. The Mitsubishi Chemical Group has positioned health care as its strategic focus in its management policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC is prioritizing work on “precision medicine” to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety, focusing on the disease areas of central nervous system and immuno-inflammation. In addition, MTPC is working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis.

https://www.mt-pharma-america.com/media/news/press-releases/2022/11/02/mitsubishi-tanabe-pharma-america-presents-interim-data-from-refine-als-biomarker-study-at-21st-annual-neals-meeting

The work in veterinary science is very exciting and massively lucrative.

OBD has used its EpiSwitch platform to develop a comprehensive pipeline of deployable molecular diagnostic tests in several indications that are being considered for commercialization.

The growing pipeline includes diagnostic/prognostic tests for early-stage detection and staging of prostate cancer and colorectal cancer, diagnostic, prognostic, predictive and monitoring tests in indications such as rheumatoid arthritis (RA), amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s Disease or motor neuron disease), multiple sclerosis (MS), lymphoma and other cancers and, in veterinary medicine, a diagnostic/prognostic test for canine lymphoma.

They are running over to UPL :-)